Abstract
Summary Etoposide and cis -platinum combination was used in 87 patients with bronchogenic squamous-cell carcinoma or adenocarcimona. The overall response rate was 41% with 4 complete responses. In patients with loco-regional disease who had not received any prior anticancer therapy, the response rate was 59% (19/32) with 3 (10%) complete responses, significantly higher ( P =0.002) than that observed in the other patients (31%). Overall, responding patients survived significantly longer ( P = 0.001) than nonresponders (median survival 63.3 weeks vs. 23.0). Toxicity was tolerable; gastrointestinal side effects were occasionally responsible for discontinuation of therapy and sepsis was the cause of death in 2 neutropenic patients. No serious nephrotoxicity was observed. The combination of etoposide and cis -platinum should probably be tested in combination with surgery or radiotherapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
